OREANDA-NEWS. August 08, 2008. The Federal Antimonopoly Service (FAS Russia) has started analyzing the market of innovative medication for treatment of seven major nosologies (myeloleukemia, enzymopathy, hypophysial nanism, hemophilia, multiple sclerosis, cystic fibrosis, and transplantation), reported the press-centre of FAS Russia. 

As part of its work, on 10th and 21st July 2008, FAS Russia requested the information necessary to determine the level of substitution from the "Roszdravnadzor Research Centre for Expert Analysis of Medications" Federal State Institution, supervised by Roszdravnadzor (the Federal Service for Supervising Health Care and Social Development).

On 4th August 2008 FAS Russia requested information from drug manufacturers: "Novartis Pharma" Ltd., "Novo Nordics" Ltd., "BERINGER INGELHAIM FHARMA GmbH", "TELERIX BIOTHERAPEUTICS Inc.", "Baxter AG" Share-Holding Company, "PHARMSTANDART-UfaVITA" OJSC, "SERONO PHARMA INTERNATIONAL", "F. Hoffman-La Roch Ltd.", "YANSSEN-SILAG International Н.В.", "ASTELLAS FHARMA EUROPE B.V.", "IVEX pharmaceuticals s.r.o.", "Teva Pharmaceuticals Industries Ltd.", "Eli Lili Vostok S.А.", "GECSAL АG", "Pfizer International LLC", and "Octapharma Nordic AB".

It is expected that based on the findings of the first stage of the project FAS Russia will determine the market shares of the drugs in question and clarify the level of substitution.

The ultimate goal of the project - including drug manufacturers in the Register of economic entities with over 35% market share of particular goods and preventing antimonopoly violations by drug manufacturers and suppliers.